Bond.az White LogoBond.az Black Logo

#bridgebio

Latest news and interesting information about bridgebio.

2026-05-22 11:53
|
473

BioMarin Neutral Rating, $50 Target by HC Wainwright

H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.

0
2026-05-21 05:21
|
654

BridgeBio SWOT: rare disease stock eyes profitability

SWOT analysis of BridgeBio Pharma: Attruby's strong launch, pipeline catalysts, and path to profitability. Rare disease stock outlook.

0
...